Sugi Predict

Sugi Predict / Compounds / SCHEMBL528177

SCHEMBL528177

SCHEMBL528177

O=C(O)c1ccc([N+](=O)[O-])c(OCc2ccccc2)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MYC P01106 4/20 0.67
▸ MAX P61244 3/20 0.67
▸ CTSV O60911 3/20 0.54
▸ CTSL P07711 3/20 0.54
▸ CASP6 P55212 1/20 0.54
▸ AKR1C3 P42330 1/20 0.52
▸ AKR1C2 P52895 1/20 0.52
▸ AKR1C1 Q04828 1/20 0.52
▸ NR4A2 P43354 2/20 0.51
▸ NR4A1 P22736 1/20 0.51
▸ NR4A3 Q92570 1/20 0.51
▸ PTGER1 P34995 1/20 0.51
▸ POLB P06746 1/20 0.51
▸ SENP8 Q96LD8 1/20 0.51
▸ SENP7 Q9BQF6 1/20 0.51
▸ SENP6 Q9GZR1 1/20 0.51
▸ TDP1 Q9NUW8 1/20 0.51
▸ L3MBTL1 Q9Y468 1/20 0.51
▸ MEN1 O00255 1/20 0.50
▸ KMT2A Q03164 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30082870 1.00 MYC (0.67) MYCMAXCTSVCTSLCASP6
SCHEMBL8534866 0.95 MYC (0.62) MYCMAXCTSVCTSLCASP6
SCHEMBL8534870 0.93 MYC (0.60) MYCMAXCTSVCTSLCASP6
SCHEMBL23628923 0.89 MYC (0.56) MYCMAXCTSVCTSLAKR1C3
SCHEMBL9274861 0.89 MYC (0.56) MYCMAXCTSVCTSLAKR1C3
SCHEMBL30049984 0.89 MYC (0.56) MYCMAXCTSVCTSLAKR1C3
SCHEMBL27620972 0.89 MAPK1 (0.57) MYCMAXCTSVCTSLAKR1C3
SCHEMBL750245 0.89 CTSV (0.63) MYCMAXCTSVCTSLCASP6
SCHEMBL12068720 0.89 MYC (0.85) MYCMAXAKR1C3AKR1C2AKR1C1
SCHEMBL30892476 0.88 MYC (0.55) MYCMAXCTSVCTSLAKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240336588-A1 COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS AVANTI BIOSCIENCES, INC. 2024-10-10 — — US disclosed
EP-4370113-A1 COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS Avanti Biosciences Inc. (US) 2024-05-22 — — EP disclosed
CN-117794526-A Compositions and methods for antioxidants and anti-inflammatory therapeutics 阿万蒂生物科学股份有限公司 2024-03-29 — — CN disclosed
US-20230287021-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING PROTEGO BIOPHARMA, INC. 2023-09-14 — — US disclosed
US-20230287021-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING PROTEGO BIOPHARMA, INC. 2023-09-14 — — US disclosed
WO-2023288020-A1 COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS AVANTI BIOSCIENCES INC. (US) 2023-01-19 — — WO disclosed
EP-4097092-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING Protego Biopharma, Inc. (US) 2022-12-07 — — EP disclosed
CN-115298168-A Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding 普罗泰格生物制药公司 2022-11-04 — — CN disclosed
US-20210346405-A1 BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS PRELUDE THERAPEUTICS INCORPORATED 2021-11-11 — — US disclosed
WO-2021222174-A1 BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS PRELUDE THERAPEUTICS INCORPORATED (US) 2021-11-04 — — WO disclosed
WO-2012015975-A2 GLP-1 RECEPTOR AGONIST COMPOUNDS HAVING STABILIZED REGIONS AMYLIN PHARMACEUTICALS, INC. (US) 2012-02-02 — — WO disclosed
WO-2012015975-A2 GLP-1 RECEPTOR AGONIST COMPOUNDS HAVING STABILIZED REGIONS AMYLIN PHARMACEUTICALS, INC. (US) 2012-02-02 — — WO disclosed
US-20030191323-A1 Hypoglycemic agent AJINOMOTO CO., INC. (JP) 2003-10-09 — — US disclosed
US-20030162818-A1 Acylsulfonamide derivative AJINOMOTO CO. INC. (JP) 2003-08-28 — — US disclosed
US-6555584-B1 Acetyl-coa carboxylase inhibitors AJINOMOTO CO., INC. (JP) 2003-04-29 — — US disclosed
EP-1300142-A1 HYPOGLYCEMICS Ajinomoto Co., Inc. (JP) 2003-04-09 — — EP disclosed
EP-0789025-B1 Substituted oxazolidinone and their use as antibacterial medicine BAYER AG (DE) 2001-04-04 — — EP disclosed
US-5792765-A ANTIBACTERIAL COMPOUNDS BAYER AKTIENGESELLSCHAFT (DE) 1998-08-11 — — US disclosed
EP-0789025-A1 Substituted oxazolidinone and their use as antibacterial medicine BAYER AG (DE) 1997-08-13 — — EP disclosed
WO-1995023143-A1 INDOLE DERIVATIVES AS TESTOSTERONE-5-ALPHA-REDUCTASE INHIBITORS PFIZER LIMITED (GB) 1995-08-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230287021-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING TTR, TTPA, TNNC1 MYC 3313/4885MAX 1082/4885CTSV 1272/4885
US-20210346405-A1 BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS BCL2, BCL2L2, BCL2L1 MYC 68/4885MAX 3412/4885CTSV 378/4885
US-20240336588-A1 COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS MPO, GPX4, GPX1 MYC 3902/4885MAX 3318/4885CTSV 929/4885
US-20030162818-A1 Acylsulfonamide derivative ACSS2, ACACA, FASN MYC 1649/4885MAX 4277/4885CTSV 2345/4885
US-20030191323-A1 Hypoglycemic agent GPR119, IAPP, SLC5A2 MYC 4511/4885MAX 4701/4885CTSV 3719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.